Statins are known to be anti-inflammatory and have been shown to both improve vascular function in RA patients with a normal lipid profile and have additional immunomodulatory and RA disease-modifying benefits, including reduction of CRP levels, serum TNF concentrations and indices of plasma viscosity, in addition to short-term improvements in endothelial function and arterial stiffness [33-37]. The gene discussed is CRP; the disease is rheumatoid arthritis.